ARSACS — Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay, OMIM #270550, a rare autosomal recessive neurodegenerative disorder caused by biallelic pathogenic variants in SACS (sacsin gene, chromosome 13q12.12; SACS encodes sacsin — a 4579-amino acid molecular co-chaperone that is one of the largest known proteins in the mammalian genome; sacsin contains multiple functional domains including an N-terminal ubiquitin-like domain, three large sacsin repeating regions (SRR) each containing an Hsp90-like ATPase domain, a central DnaJ domain enabling co-chaperone function with Hsc70, and a C-terminal CHORD domain and UBL domain; sacsin localizes primarily to the cytoplasm and dendritic processes of neurons — particularly Purkinje cells in the cerebellar cortex — where it is proposed to function in protein quality control and mitochondrial network fission/fusion dynamics; SACS deficiency in Purkinje cells disrupts protein homeostasis and mitochondrial morphology, leading to progressive Purkinje cell degeneration and the cerebellar ataxia that is the hallmark of ARSACS; the peripheral nerve pathology in ARSACS — axonal and demyelinating peripheral neuropathy — reflects sacsin's expression in dorsal root ganglion neurons and peripheral nerve axons; the spastic paraparesis that distinguishes ARSACS from most other recessive ataxias reflects corticospinal tract involvement); originally described in 1978 by Bouchard and colleagues in the Charlevoix-Saguenay region of northeastern Quebec, Canada, where the ARSACS founder effect produces an extraordinarily high carrier frequency exceeding 1 in 22 individuals — with the classic Quebec founder mutations c.5254C>T (p.Arg1752*) and the large deletion covering exon 1 accounting for the great majority of Quebec alleles — making ARSACS the most common recessive ataxia in Quebec and among the most common worldwide; now recognized globally with SACS pathogenic variants identified in multiple ethnic backgrounds across all continents, with the worldwide clinical phenotype substantially similar to the Quebec founder-effect population; the clinical phenotype of ARSACS is characterized by early-onset cerebellar ataxia (gait ataxia typically manifest as the child begins walking at 12–18 months — children may be late walking or may walk with an ataxic gait from first steps, becoming the presenting concern; appendicular ataxia develops subsequently), progressive spasticity of lower limbs that increases over time and is a clinically distinguishing feature among recessive ataxias (spastic paraparesis with lower limb hyperreflexia, extensor plantar responses — spasticity progresses to become the major contributor to gait deterioration and functional decline in many patients; an ARSACS patient who could walk with mild ataxia at age 20 may be significantly gait-impaired by combined ataxia and spasticity by age 35), peripheral neuropathy (axonal and demyelinating mixed neuropathy confirmed on nerve conduction studies — reduced amplitude sensory and motor potentials with slowed conduction velocity; clinical manifestations include distal sensory loss, areflexia — paradoxically the combination of spasticity and areflexia is a diagnostic clinical clue in ARSACS), ocular features that are among the most specific findings in ARSACS and identifiable even in young children (retinal hypermyelination — thickened, yellowish-white opaque myelinated nerve fibers radiating from the optic disc giving a "dirty disc" or "brush-fire" appearance on fundoscopy; this finding is present in the great majority of ARSACS patients including non-Quebec cases and has been proposed as a reliable clinical identifier even before molecular confirmation), dysarthria (cerebellar dysarthria — scanning, irregular speech pattern; progressive over the disease course), and nystagmus (gaze-evoked nystagmus common, various forms reported); brain MRI demonstrates cerebellar vermis atrophy (consistent and early finding), linear pontine T2 signal abnormalities (horizontal linear hyperintensities through the pons — a characteristic MRI finding that reflects pontocerebellar fiber degeneration and may be pathognomonic for ARSACS when combined with the clinical phenotype), and atrophy of the superior cerebellar peduncles; the clinical course is slowly progressive — most patients remain ambulatory into the 3rd to 4th decade but wheelchair dependency typically occurs by the 4th to 5th decade; care technology platforms for ARSACS coordinate cerebellar ataxia progression monitoring (SARA — Scale for Assessment and Rating of Ataxia serial records), spasticity management coordination (baclofen dosing records, physiotherapy adherence), peripheral neuropathy assessment scheduling (nerve conduction studies intervals, neuropathic pain management records), ophthalmology assessments (retinal hypermyelination documentation, visual acuity), speech and language therapy session scheduling (dysarthria progression documentation), wheelchair and mobility aid coordination platforms, neuroimaging surveillance interval scheduling (serial MRI for cerebellar and pontine progression tracking), physiotherapy and occupational therapy session scheduling, and genetic counseling documentation platforms.
ARSACS technology platforms — encompassing the molecular genetics laboratories where SACS biallelic pathogenic variant identification by targeted Quebec founder mutation analysis, gene sequencing, or exome/genome sequencing confirms the molecular diagnosis and enables genetic counseling; the cerebellar ataxia monitoring platforms — SARA scale serial administration scheduling tools, ataxia rating scale records, pediatric and adult neurology encounter records, International Cooperative Ataxia Rating Scale (ICARS) records where used — capturing the trajectory of cerebellar ataxia across the ARSACS disease course; the spasticity assessment and management platforms — Modified Ashworth Scale serial assessment records, physiotherapy coordination systems, baclofen prescription and titration records, botulinum toxin injection scheduling platforms, and intrathecal baclofen pump management systems where applicable; the peripheral neuropathy monitoring scheduling systems — nerve conduction study scheduling tools, neurophysiology coordination platforms, neuropathic pain medication management records; the ophthalmology assessment platforms — retinal hypermyelination documentation systems, fundoscopy and OCT scheduling tools, visual acuity monitoring records; the speech and language therapy coordination platforms managing dysarthria assessment, communication adaptation records, and AAC device coordination as speech deteriorates; the wheelchair and adaptive equipment coordination platforms managing the mobility aid transition that occurs as combined ataxia and spasticity progress to wheelchair dependency; the neuroimaging surveillance platforms — serial brain MRI scheduling systems, cerebellar atrophy quantification records, pontine T2 signal documentation tools; the physiotherapy and occupational therapy session scheduling platforms coordinating the multi-disciplinary rehabilitation that is central to ARSACS functional maintenance; and the genetic counseling and cascade testing coordination platforms managing the autosomal recessive family cascade implications and the particularly complex genetic counseling required in the high-prevalence Charlevoix-Saguenay region where carrier frequency exceeds 1 in 22 individuals — must maintain availability and performance standards matched to the ataxia monitoring urgency, spasticity management requirements, and multi-specialty rehabilitation coordination demands of modern ARSACS care. This guide explains why ARSACS tech platforms need dedicated monitoring, what to monitor, and how to build a monitoring strategy matched to the ataxia progression tracking urgency and rehabilitation coordination requirements of ARSACS care.
Why ARSACS Tech Platforms Require Specialized Monitoring Attention
ARSACS management is defined by several clinically urgent platform requirements: the ataxia progression monitoring urgency — ARSACS is a slowly but inexorably progressive cerebellar ataxia in which the trajectory of SARA score decline over time informs rehabilitation intensity decisions, physiotherapy goal-setting, mobility aid progression, and the timing of the wheelchair transition discussion; SARA scheduling and records platform availability is required at every neurology encounter to capture the ataxia trajectory that guides multi-disciplinary management; the spasticity management urgency — lower limb spasticity in ARSACS is progressive and requires ongoing pharmacological and physiotherapy management; baclofen titration records and physiotherapy session documentation require platform availability to support coordinated spasticity management across neurology and rehabilitation; the peripheral neuropathy monitoring urgency — the mixed axonal and demyelinating peripheral neuropathy in ARSACS requires periodic nerve conduction study surveillance and neuropathic pain management; NCS scheduling and neuropathic pain medication records require platform availability to maintain the neuropathy monitoring schedule; the ophthalmology monitoring urgency — the retinal hypermyelination in ARSACS requires documentation for diagnostic purposes and ophthalmology assessment scheduling; fundoscopy and OCT records require platform availability to maintain the ophthalmic assessment schedule; and the genetic counseling urgency — ARSACS is autosomal recessive with particularly complex population genetics implications in the Charlevoix-Saguenay region where the high carrier frequency means that affected individuals have an elevated risk of reproductive partner carrier status; genetic counseling coordination platform availability is required for the cascade testing and reproductive counseling that ARSACS families require.
Molecular genetic testing platforms establish SACS biallelic pathogenic variant confirmation and ARSACS diagnosis. Targeted founder mutation analysis and gene sequencing enable genetic counseling and family cascade testing. Monitor at 1-minute intervals during laboratory hours.
Cerebellar ataxia monitoring platforms coordinate serial SARA assessments. Ataxia trajectory documentation at each neurology encounter requires scheduling and records platform availability. Monitor at 1-minute intervals during clinical hours.
Spasticity assessment and management platforms coordinate baclofen titration and physiotherapy. Progressive lower limb spasticity management requires scheduling and records platform availability. Monitor at 1-minute intervals during clinical hours.
Peripheral neuropathy monitoring platforms schedule NCS intervals and pain management. Axonal and demyelinating neuropathy surveillance and neuropathic pain medication records require platform availability. Monitor at 1-minute intervals during clinical hours.
Ophthalmology scheduling platforms coordinate retinal hypermyelination documentation and visual monitoring. Fundoscopy and OCT scheduling and result records require platform availability. Monitor at 1-minute intervals during clinical hours.
SLP and rehabilitation coordination platforms manage dysarthria and multi-disciplinary rehabilitation. Dysarthria progression records, PT/OT session scheduling, and AAC coordination require platform availability. Monitor at 1-minute intervals during clinical hours.
What to Monitor on an ARSACS Tech Platform
Molecular Genetic Testing — SACS Biallelic Pathogenic Variant Identification
Monitor SACS molecular testing and variant characterization records (targeted Quebec founder mutation analysis — c.5254C>T [p.Arg1752*] and exon 1 deletion for Quebec patients; SACS full gene sequencing for non-Quebec patients or Quebec patients without founder mutations; exome or genome sequencing records for complex cases; ACMG variant classification records for non-founder variants; multigene recessive ataxia panel records where used — distinguishing ARSACS from Friedreich ataxia [FXN], AOA1 [APTX], AOA2 [SETX], and other recessive ataxias; protein modeling and functional data records where used to assess novel variant pathogenicity), genetic counseling records (autosomal recessive inheritance counseling — 25% recurrence risk for parents who are both carriers; carrier status testing records for siblings and parents; partner carrier testing recommendation records — particularly urgent in the Charlevoix-Saguenay region where 1 in 22 individuals is a SACS carrier; reproductive options counseling records where applicable — pre-implantation genetic diagnosis, prenatal diagnosis; ARSACS patient registry enrollment — Euro-ATAXIA registry, ARSACS Research Foundation registry; ophthalmology referral initiation at diagnosis for retinal hypermyelination assessment; NCS referral at diagnosis for peripheral neuropathy documentation at baseline), and cousin risk documentation (expanded carrier testing recommendations where multiple family members in close-knit Charlevoix-Saguenay communities may have SACS carrier status due to high carrier frequency) at 1-minute intervals during laboratory hours. Alert immediately — SACS molecular testing platform failures during the genetic evaluation of a 4-year-old Quebec girl presenting to the pediatric neurology clinic with progressive gait ataxia since first steps, lower limb hyperreflexia despite sensory loss (paradoxical examination finding), and retinal hypermyelination identified by the referring ophthalmologist — when SACS biallelic variant identification confirms ARSACS, establishes the diagnosis that the retinal hypermyelination finding was identifying, initiates the rehabilitation program with physiotherapy and OT, refers to SLP for baseline dysarthria assessment, enrolls the family in the ARSACS registry, and provides the carrier status information that informs the family's reproductive counseling in the context of the high community carrier frequency.
Cerebellar Ataxia Progression Monitoring — SARA and ICARS Serial Assessment
Monitor serial ataxia rating scale records (Scale for Assessment and Rating of Ataxia [SARA] serial administration records at 6–12 month intervals — SARA total score, subscale scores [gait, stance, sitting, speech, finger-chase, nose-finger test, fast alternating hand movements, heel-shin slide]; SARA trajectory documentation across serial assessments; gait analysis records where available — video gait analysis records, timed 10-meter walk test, timed 25-foot walk for high-functioning patients; International Cooperative Ataxia Rating Scale [ICARS] records where used as alternative or supplementary rating scale; clinical neurology encounter records documenting ataxia severity, spasticity severity, and neuropathy symptoms at each visit), functional disability documentation (9-Hole Peg Test records — upper limb ataxia quantification; Timed Up and Go test records; PROM-Ataxia patient-reported outcome measures records; Barthel Index or FIM records where used; disability scale records documenting transition from independent ambulation to walking aid to wheelchair dependency), and ataxia natural history records (ARSACS-specific natural history cohort records where the patient is enrolled; serial functional endpoint records for clinical trial readiness documentation) at 1-minute intervals during clinical hours. Alert immediately — SARA assessment scheduling platform failures preventing the neurologist from administering and recording the SARA total score for a 32-year-old ARSACS patient at their annual ataxia review — when the serial SARA documentation of a 2-point decline per year over 3 consecutive assessments represents the progression trajectory that informs the neurologist's recommendation to initiate physiotherapy with balance training intensification, prescribe an ankle-foot orthosis to address foot-drop contributing to falls, and discuss the timeline for the walking frame to wheelchair transition planning that the patient and family are not yet ready to address but that the SARA trajectory indicates is approaching.
Spasticity Management — Baclofen, Physiotherapy, and Botulinum Toxin Coordination
Monitor spasticity assessment records (Modified Ashworth Scale [MAS] serial lower limb records at neurology encounters — hip adductor, knee extensor, and ankle plantar flexor spasticity grading; Tardieu Scale records where used; lower limb tone pattern documentation — bilateral symmetric spastic paraparesis characteristic of ARSACS; functional impact of spasticity on gait — interaction between cerebellar ataxia and spasticity in determining ambulatory status; falls related to spasticity-exacerbated gait instability), baclofen prescription and titration records (oral baclofen dose titration records — starting dose, dose escalation records, target dose documentation; baclofen tolerability documentation [sedation, weakness at high doses]; baclofen response records — MAS improvement, functional gait change; intrathecal baclofen pump records where oral baclofen is insufficient — pump implantation records, pump programming records, refill scheduling, pump interrogation records), botulinum toxin injection scheduling and records (toxin injection scheduling records for focal spasticity in gastrocnemius, tibialis posterior, or hip adductors where appropriate; injection site and dose records; EMG-guidance records where used; response assessment records at 4–6 weeks post-injection; injection interval scheduling), and physiotherapy session and programme records (PT session scheduling and records — lower limb stretching and range-of-motion exercise records; gait training records; balance exercise records; adaptive equipment progression records — walking stick, walking frame, rollator, mobility scooter, manual wheelchair, power wheelchair; hydrotherapy session records where available) at 1-minute intervals during clinical hours.
Peripheral Neuropathy Monitoring — NCS Intervals and Neuropathic Pain Management
Monitor nerve conduction study scheduling and result records (NCS scheduling at baseline and surveillance intervals [typically every 2–3 years or when new symptoms develop]; NCS result records — motor nerve conduction velocity, compound motor action potential amplitude, sensory nerve action potential amplitude, distal motor latency across ulnar, median, peroneal, tibial, sural, and radial nerves; pattern characterization records — mixed axonal and demyelinating neuropathy pattern; serial NCS records documenting progression of neuropathic changes over time), EMG records (needle EMG records documenting denervation in distal muscles — fibrillation potentials, positive sharp waves; chronic reinnervation changes; motor unit action potential analysis), clinical neuropathy assessment records (sensory examination records — vibration, proprioception, pinprick, temperature; clinical correlation with NCS findings; ankle reflex and other deep tendon reflex records — areflexia characteristic of ARSACS neuropathy; gait contribution of peripheral neuropathy documentation), and neuropathic pain management records (neuropathic pain assessment records — NRS pain score, neuropathic symptom descriptors; pregabalin or gabapentin prescription and dose titration records for neuropathic pain; amitriptyline or duloxetine records where used; neuropathic pain response documentation) at 1-minute intervals during clinical hours.
Ophthalmology Assessment — Retinal Hypermyelination and Visual Function Monitoring
Monitor ophthalmology assessment scheduling and result records (fundoscopy scheduling and result records — retinal hypermyelination grading records: thickened yellowish-white opacified myelinated nerve fiber layer radiating from the optic disc; hypermyelination extent and distribution documentation; comparison to prior fundoscopy records documenting stability [retinal hypermyelination is typically stable rather than progressive in ARSACS]; optic coherence tomography [OCT] scheduling and result records — retinal nerve fiber layer thickness; macular thickness records; serial OCT records), visual acuity assessment records (visual acuity records in Snellen or logMAR — typically preserved in ARSACS despite retinal hypermyelination but requires monitoring; color vision testing records; visual field records where indicated), nystagmus documentation (gaze-evoked nystagmus characterization records; neuro-ophthalmology records where horizontal or vertical nystagmus requires specialist evaluation), and driving assessment records (visual and motor driving assessment records where patients are licensed drivers — ARSACS affects both vision [nystagmus] and coordination, creating dual driving impairment risk; DVLA or transport authority notification records where applicable) at 1-minute intervals during clinical hours.
Speech and Language Therapy — Dysarthria Progression and AAC Coordination
Monitor SLP assessment and session records (SLP dysarthria assessment records — Robertson Dysarthria Profile or Frenchay Dysarthria Assessment; cerebellar dysarthria characterization records [irregular articulatory breakdown, variable rate and rhythm, scanning speech]; speech intelligibility rating records — conversational intelligibility percentage; SLP session scheduling and treatment records — articulation therapy, prosody training, breath support exercises; serial dysarthria severity documentation), AAC evaluation and device coordination records (AAC evaluation records — timing of evaluation relative to dysarthria severity; AAC device trial records; device prescription records; AAC setup and programming records; communication partner training records; voice banking records where initiated early to capture natural voice for later use in AAC systems), and communication accommodation records (written communication adaptation records; email and messaging platform use records as verbal communication declines; work and educational accommodation documentation for dysarthria) at 1-minute intervals during clinical hours.
Wheelchair and Mobility Aid Progression Coordination
Monitor mobility aid prescription and coordination records (walking stick prescription and fitting records; walking frame and rollator prescription records; AFO prescription and fitting records — foot-drop management; manual wheelchair prescription records — seat dimensions, backrest support, footrest configuration; power wheelchair assessment and prescription records where manual propulsion becomes insufficient; mobility scooter assessment records; seating and positioning clinic records), home and environmental modification records (home OT assessment records — stair assessment, bathroom grab rail installation, threshold management; ramp prescription records; hospital bed and pressure care equipment records), transport coordination records (wheelchair-accessible vehicle assessment records; Mobility Scheme or adaptive vehicle records where applicable; transport to rehabilitation and clinical appointments records), and disability benefits coordination records (medical certificate and supporting documentation for disability benefit applications related to ARSACS functional impairment) at 1-minute intervals during clinical hours.
Neuroimaging Surveillance — Cerebellar and Pontine Progression
Monitor serial brain MRI scheduling and result records (routine surveillance brain MRI scheduling — typically every 2–3 years unless clinical progression warrants more frequent assessment; brain MRI result documentation — cerebellar vermis atrophy quantification [vermis area on midline sagittal, cerebellar hemisphere volume]; pontine T2 signal documentation — linear horizontal T2 hyperintensities through the pons characteristic of ARSACS [pontocerebellar fiber degeneration pattern]; superior cerebellar peduncle atrophy records; spinal cord MRI records where spastic paraparesis is severe enough to warrant cervical cord assessment — excluding superimposed structural cord pathology), and neuroradiology coordination records (neuroradiology reporting records; neurology interpretation records; comparative records documenting interval change in cerebellar volume and pontine T2 signal across serial MRIs; MRI-clinical correlation records) at 1-minute intervals during clinical hours.
Genetic Counseling and Population-Specific Cascade Testing
Monitor genetic counseling encounter records (initial and follow-up genetic counseling records; autosomal recessive inheritance counseling; population-specific counseling for Quebec Charlevoix-Saguenay patients — explained carrier frequency >1/22, partner carrier testing urgency; partner carrier testing records — SACS mutation analysis for the reproductive partner of an ARSACS-affected individual; reproductive option records where both partners are confirmed carriers; cascade testing in siblings records — 2/3 probability carrier among unaffected siblings), Quebec-specific genetic epidemiology records (community carrier screening records where relevant — the Quebec carrier screening program history context; pediatric diagnosis records — ARSACS is now often diagnosed in early childhood in Quebec given the clinical recognition and molecular testing availability; community support and advocacy records — ARSACS Research Foundation community engagement records) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. ARSACS management coordinates across molecular genetics, pediatric and adult neurology, neurophysiology, ophthalmology, physiotherapy, occupational therapy, speech and language therapy, rehabilitation medicine, and rare disease registries — authentication failures block the multi-specialty team during clinical encounters where SARA ataxia scores, NCS results, baclofen titration records, ophthalmology hypermyelination documentation, and SLP dysarthria records must all be simultaneously accessible.
SSL Certificates
Monitor SSL certificate expiry across all molecular testing platforms, ataxia rating scale scheduling systems, NCS scheduling tools, ophthalmology assessment platforms, physiotherapy session records systems, and rehabilitation coordination platforms. Certificate errors disrupting spasticity management records access during a baclofen dose review or ataxia rating scale records during an annual neurology encounter create direct patient care quality risks.
HIPAA and Rare Disease Privacy Considerations for ARSACS
ARSACS technology platforms handle molecular genetic records (SACS biallelic pathogenic variants, carrier status for parents and siblings — with particular sensitivity in the Charlevoix-Saguenay community setting where genetic carrier status may have community-level social implications in a high-carrier-frequency founder population), neuroimaging records (serial brain MRI with cerebellar atrophy and pontine T2 signal progression documentation), nerve conduction study records (peripheral neuropathy progression documentation), ophthalmology records (retinal hypermyelination — diagnostic documentation), dysarthria and communication assessment records, and progressive disability and mobility aid documentation across the ARSACS lifespan.
Alerting Strategy for ARSACS Tech Platforms
Immediate laboratory-hours alerting for molecular genetic testing platforms: SACS biallelic variant identification — the diagnosis initiating the rehabilitation program, ophthalmology referral, NCS baseline, and family cascade testing.
Immediate clinical-hours alerting for cerebellar ataxia monitoring platforms: Serial SARA assessment records — ataxia trajectory documentation requires scheduling and records platform availability at each neurology encounter.
Immediate clinical-hours alerting for spasticity assessment and management platforms: Baclofen titration records, physiotherapy session documentation, and botulinum toxin scheduling.
Immediate clinical-hours alerting for peripheral neuropathy monitoring platforms: NCS scheduling and result records, neuropathic pain management, and nerve conduction study coordination.
Immediate clinical-hours alerting for ophthalmology scheduling platforms: Retinal hypermyelination documentation, OCT scheduling, and visual function monitoring.
Immediate clinical-hours alerting for SLP and dysarthria management platforms: Dysarthria assessment records, AAC evaluation coordination, and communication adaptation documentation.
Immediate clinical-hours alerting for wheelchair and mobility aid coordination platforms: Mobility aid prescription records, seating clinic records, and home modification coordination.
Sustained-failure alert (10–15 minutes): ARSACS research registry records, community genetic counseling coordination records, and transport accessibility records.
30-day advance warning: SSL certificates across all platforms.
Status Page for ARSACS Care Team Communication
A real-time status page gives molecular genetics laboratories, pediatric and adult neurologists, neuroradiologists, neurophysiologists, ophthalmologists, physiotherapists and occupational therapists, speech and language therapists, rehabilitation medicine specialists, wheelchair and seating clinic teams, genetic counselors, ARSACS Research Foundation registry coordinators, and caregiver support teams immediate platform visibility without requiring inbound IT support contact.
Vigilmon Setup for ARSACS Tech Platforms
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | SACS molecular testing and biallelic variant identification | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling and cascade testing coordination | 1 min | Slack + PagerDuty (lab hours) | | Serial SARA ataxia assessment records | 1 min | Slack + PagerDuty (clinical hours) | | Gait analysis and functional disability documentation | 1 min | Slack + PagerDuty (clinical hours) | | Spasticity assessment (MAS) and baclofen titration records | 1 min | Slack + PagerDuty (clinical hours) | | Botulinum toxin injection scheduling and response records | 1 min | Slack + PagerDuty (clinical hours) | | Physiotherapy session scheduling and programme records | 1 min | Slack + PagerDuty (clinical hours) | | NCS scheduling and peripheral neuropathy monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Neuropathic pain assessment and medication records | 1 min | Slack + PagerDuty (clinical hours) | | Ophthalmology scheduling and retinal hypermyelination documentation | 1 min | Slack + PagerDuty (clinical hours) | | SLP dysarthria assessment and AAC coordination | 1 min | Slack + PagerDuty (clinical hours) | | Wheelchair and mobility aid coordination records | 1 min | Slack + PagerDuty (clinical hours) | | Serial brain MRI scheduling and cerebellar/pontine tracking | 1 min | Slack + PagerDuty (clinical hours) | | ARSACS registry and research participation records | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure SACS molecular testing platforms with immediate laboratory-hours alerting
- Add genetic counseling and cascade testing coordination platforms with immediate laboratory-hours alerting — partner carrier testing is particularly urgent in high-carrier-frequency populations
- Configure serial SARA ataxia assessment records with immediate clinical-hours alerting — ataxia trajectory at every neurology encounter is the primary disease monitoring tool
- Add gait analysis and functional disability documentation with immediate clinical-hours alerting
- Configure spasticity assessment and baclofen titration records with immediate clinical-hours alerting
- Add botulinum toxin injection scheduling and response records with immediate clinical-hours alerting
- Configure physiotherapy session scheduling and programme records with immediate clinical-hours alerting
- Add NCS scheduling and peripheral neuropathy monitoring with immediate clinical-hours alerting
- Configure neuropathic pain assessment and medication records with immediate clinical-hours alerting
- Add ophthalmology scheduling and retinal hypermyelination documentation with immediate clinical-hours alerting
- Configure SLP dysarthria assessment and AAC coordination with immediate clinical-hours alerting
- Add wheelchair and mobility aid coordination records with immediate clinical-hours alerting — mobility aid progression documentation is a central functional milestone tracking requirement
- Configure serial brain MRI scheduling and cerebellar/pontine progression tracking with immediate clinical-hours alerting
- Add ARSACS registry and research participation records with sustained-failure alerting during business hours
- Enable SSL certificate monitoring across all platforms
- Add the status page URL to ARSACS neurology downtime protocols, rehabilitation coordination procedures, and multi-specialty care team communication channels
Conclusion
ARSACS technology platforms are embedded in clinical decisions where ataxia rating scale platform availability — when the neurologist must access the serial SARA total scores for a 38-year-old ARSACS patient who uses a rollator walker and reports that over the past 6 months she has fallen twice in the community and is noticing that her walker is "not enough anymore" — cannot be disrupted by ataxia assessment platform failures that withhold the serial SARA documentation showing a 3-point decline in gait and stance subscores over 18 months and a total SARA score of 18/40, because the trajectory documented in the serial records is the clinical evidence that justifies the wheelchair assessment referral that the patient, who is a 38-year-old mother who uses the rollator to get her children to school and is not emotionally prepared for a wheelchair, requires a clinician to present with empathy, specificity about the clinical data, and a clear explanation of how the wheelchair will restore rather than diminish her functional independence; where spasticity management platform availability — when the physiotherapist must access the current baclofen dose and the most recent Modified Ashworth Scale assessment for a 29-year-old ARSACS patient attending physiotherapy for gait training — is the platform availability requirement that determines whether the physiotherapist can coordinate with the prescribing neurologist about the patient's report that the current baclofen dose is causing daytime sedation and that the lower limb spasticity in hip adductors is limiting the physiotherapy goal of improving step length; where ophthalmology scheduling platform availability — when the referring pediatrician must schedule the ophthalmology assessment for an 8-year-old child with progressive gait ataxia in whom the clinical question is whether the retinal hypermyelination finding on direct ophthalmoscopy performed in clinic is genuine hypermyelination or a normal variant, and whether confirmation of retinal hypermyelination should immediately trigger SACS genetic testing — determines whether the diagnostic workup proceeds with the ophthalmology documentation that will drive the molecular genetic testing order; and where peripheral neuropathy monitoring platform availability — when the neurologist must access the serial NCS records for a 45-year-old ARSACS patient who is reporting new distal burning pain in the feet — determines whether the neurophysiology results documenting progressive axonal neuropathy over the past 5 years of NCS surveillance are available to contextualize the new neuropathic pain symptoms as neuropathy progression warranting pregabalin initiation rather than a new-onset peripheral neuropathy requiring a separate diagnostic evaluation.
Uptime monitoring gives ARSACS tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to molecular genetics laboratories, pediatric and adult neurologists, neurophysiologists, ophthalmologists, physiotherapists, occupational therapists, speech and language therapists, rehabilitation medicine specialists, genetic counselors, ARSACS registry coordinators, and compliance auditors that platform operational reliability matches the ataxia progression monitoring urgency, spasticity management requirements, and multi-disciplinary lifelong rehabilitation coordination demands of modern ARSACS management.
Start monitoring your ARSACS care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #ARSACS #SACS #sacsin #ataxia #spastic #Charlevoix #Saguenay #Quebec #cerebellar #SARA #spasticity #baclofen #peripheralneuropathy #NCS #retinal #hypermyelination #dysarthria #AAC #wheelchair #raredisease #founderpopulation #HIPAA #healthtech #digitalhealth #uptime #sre